Making Naloxone More Available to Prevent Opioid Overdose
Improving Access to Naloxone to Prevent Opioid Overdose Deaths Within Community-based Programs that Serve People Who Use Drugs
This project helps community programs give out more naloxone, a life-saving medication, to people who use drugs across California to prevent overdose deaths.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Triangle Institute NIH-funded |
| Lab location | 1 site (Research Triangle Park, United States) |
| Project ID | NIH-11121958 on NIH RePORTER |
What this research studies
We are testing a new way to help community programs better distribute naloxone, which can reverse opioid overdoses. This approach, called SAIA-Naloxone, guides programs through steps like screening participants, providing training on how to use naloxone, and ensuring people can get refills. Our goal is to make sure more people who use drugs have access to naloxone when they need it most. We are conducting a large-scale comparison to see how well this method works and if it is cost-effective.
Who could benefit from this research
Good fit: This project is designed to benefit people who use drugs and are served by community-based programs in California, by increasing their access to naloxone.
Not a fit: Patients not served by the participating community-based programs in California may not directly benefit from this specific intervention.
Why it matters
Potential benefit: If successful, this work could significantly reduce opioid overdose deaths by making naloxone more widely available and effectively distributed through community programs.
How similar studies have performed: Pilot work has shown that this approach led to a significant increase in the number of people receiving naloxone and doses distributed per week.
Where this research is happening
Research Triangle Park, United States
- Research Triangle Institute — Research Triangle Park, United States (Active)
Researchers
- Principal investigator: Lambdin, Barrot Hopkins — Research Triangle Institute
- Study coordinator: Lambdin, Barrot Hopkins
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.